Potential Involvement of Sulfotransferase in the Mechanism of Lamotrigine-induced Skin Rash.
Journal
Chemical research in toxicology
ISSN: 1520-5010
Titre abrégé: Chem Res Toxicol
Pays: United States
ID NLM: 8807448
Informations de publication
Date de publication:
20 Nov 2023
20 Nov 2023
Historique:
pmc-release:
03
11
2024
medline:
21
11
2023
pubmed:
3
11
2023
entrez:
3
11
2023
Statut:
ppublish
Résumé
The mechanism of drug-induced skin rash is not well understood. Circumstantial evidence suggests that the covalent binding of a reactive metabolite is involved in the mechanism of most idiosyncratic drug reactions. However, there is a limited quantity of drug metabolizing enzymes in the skin, except for sulfotransferases. It is possible that some drugs are metabolized to reactive sulfate metabolites that are responsible for skin rashes. For example, nevirapine-induced skin rash involves metabolism of nevirapine to 12-hydroxy-nevirapine, which is further metabolized by sulfotransferase in the skin to a reactive benzylic sulfate that covalently binds to proteins. The working hypothesis is that lamotrigine, valdecoxib, and sertraline skin rashes involve the formation of reactive sulfate in the skin. Lamotrigine-
Identifiants
pubmed: 37922508
doi: 10.1021/acs.chemrestox.3c00187
pmc: PMC10664754
doi:
Substances chimiques
Lamotrigine
U3H27498KS
valdecoxib
2919279Q3W
Nevirapine
99DK7FVK1H
Sertraline
QUC7NX6WMB
Sulfotransferases
EC 2.8.2.-
Oxides
0
Sulfates
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1711-1716Références
Skin Pharmacol. 1994;7(6):335-9
pubmed: 7946376
Chem Res Toxicol. 2013 May 20;26(5):817-27
pubmed: 23590230
Biochem Pharmacol. 2018 May;151:104-113
pubmed: 29524394
J Invest Dermatol. 1983 Jul;81(1 Suppl):141s-4s
pubmed: 6190959
Chem Res Toxicol. 2017 Jan 17;30(1):295-314
pubmed: 27775332
PLoS One. 2014 Aug 19;9(8):e105409
pubmed: 25136834
Chem Res Toxicol. 2000 Nov;13(11):1075-81
pubmed: 11087428
Nat Chem Biol. 2023 Jul;19(7):855-864
pubmed: 36805701
Chem Res Toxicol. 2010 Jan;23(1):159-70
pubmed: 19961160
Drug Metab Dispos. 2009 Nov;37(11):2255-61
pubmed: 19679676
Chem Biol Interact. 2016 Nov 25;259(Pt A):2-7
pubmed: 27174136
Can J Neurol Sci. 1998 Nov;25(4):S14-8
pubmed: 9827240
Drug Metab Dispos. 2005 Feb;33(2):262-70
pubmed: 15547048
Biochem Pharmacol. 1999 Aug 15;58(4):605-16
pubmed: 10413297
Biochim Biophys Acta. 2002 Nov 14;1573(2):165-70
pubmed: 12399026
Xenobiotica. 2016 Jul;46(7):612-619
pubmed: 26577053
J Invest Dermatol. 2008 Jan;128(1):35-44
pubmed: 17805350
Mol Cell Endocrinol. 2005 Aug 30;240(1-2):32-42
pubmed: 16024168
Hum Mol Genet. 2007 Mar 1;16(5):463-70
pubmed: 17189289
Drug Metab Dispos. 2007 Jul;35(7):1050-6
pubmed: 17409271
Biochem Biophys Res Commun. 2000 Oct 14;277(1):236-45
pubmed: 11027669
Biochem Biophys Res Commun. 2000 Jan 7;267(1):80-4
pubmed: 10623578
Epilepsia. 1999 Jul;40(7):985-91
pubmed: 10403224
Drug Metab Dispos. 1989 Sep-Oct;17(5):542-50
pubmed: 2573498
Gene. 2002 Feb 20;285(1-2):39-47
pubmed: 12039030
Drug Metab Dispos. 2002 Sep;30(9):1013-21
pubmed: 12167567
Exp Ther Med. 2019 Dec;18(6):5061-5071
pubmed: 31798726
Drug Metab Rev. 2007;39(4):659-98
pubmed: 18058329
World Allergy Organ J. 2008 Jun;1(6):96-102
pubmed: 23282405
Cell. 2003 Jul 25;114(2):161-70
pubmed: 12887918
Biosci Biotechnol Biochem. 1998 May;62(5):1037-40
pubmed: 9648242